Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New biomarkers for improving treatment of spondylarthritis

29.05.2006
Analysis of synovial tissue indicates changes in inflammatory and immune cells correlating with patient response to anti-TNFá therapy
Clinical trials are essential to the development of effective treatments for chronic autoimmune arthritis. For ethical, practical, and financial reasons, researchers increasingly face the challenge of achieving proof-of-concept in early-phase clinical trials of limited size, limited duration, and minimal patient risk. Analysis of tissue from the synovium, the thin membrane lining the joint space and primary target of inflammation, provides a straightforward way to meet this challenge. This approach has been used extensively, and proven valuable, in studies of rheumatoid arthritis (RA).

Spondylarthritis (SpA) refers to a group of chronic autoimmune arthritic conditions, including ankylosing spondylitis (AS) and the arthritis associated with psoriasis and inflammatory bowel diseases, primarily affecting peripheral joints. For an international alliance of researchers, synovial tissue analysis presented an ideal vehicle for identifying biomarkers of SpA. Their findings, featured in the June 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), hold the promise to facilitate the progress of clinical trials dedicated to improving the treatment of SpA.

Led by Dr. Dominique Baeten at the University of Amsterdam’s Academic Medical Center, the 12-week study included 52 patients who met established criteria for SpA. Patients were randomly divided into three groups. Two groups were treated with a tumor necrosis factor (TNFá) blockade – 20 received infliximab and 20 received etanercept. None of these 40 patients was being treated with a disease-modifying antirheumatic drug (DMARD). The remaining 12 patients served as controls. At the study’s inception and again at its culmination, each patient participated in a thorough assessment of disease symptoms and pain.

At the same intervals, weeks 0 and 12, synovial biopsies were performed on each patient, through needle arthroscopy of the knee. The synovial tissue samples were then subjected to extensive evaluation. The laboratory tests included measures of abnormal cell growth in the lining layer, vascular growth, markers of cellular infiltration, and metalloproteinases (MMPs) in the lining and sub-lining layers.

In both the anti-TNFá treatment groups, patients experienced significant improvements in disease activity, pain, and swollen and tender joint counts. In contrast, there was no improvement in the control group; in fact, there was a significant deterioration in patient assessment of pain. But the most noteworthy findings came from the analysis of whether changes in synovial tissue correlated with changes in disease activity between patients who had received effective treatment and those who had not.

Among the synovial features linked to anti-TNFá effectiveness, the researchers found changes in subsets of synovial macrophages, a type of white blood cell; changes in the levels of polymorphonuclear (PMN) cells, which work to fight infection; and changes in MMP-3 expression. Taken together, these findings indicate that, for SpA patients in particular, changes in disease activity are accompanied by series of distinct and measurable events in the peripheral joint.

To affirm these findings and strengthen their clinical application, the researchers also found that the same synovial features showed a highly different standardized response means between SpA patients receiving effective treatment and control patients. In validation analyses with independent synovial tissue samples, effective treatment was correctly predicted in 24 of 30 SpA patients.

As Dr. Baeten observes, these tiny changes in synovial tissue have the potential to be a great research and therapeutic asset. "Their ability to correctly discriminate between effective and ineffective treatment in small patient cohorts makes than interesting biomarkers to facilitate conclusive early phase clinical trials in SpA," he notes. "Further studies are needed to confirm their value as biomarkers at early time points across different therapeutic regimens and to combine synovial assessment with predictors of axial response to treatment in SpA."

Amy Molnar | EurekAlert!
Further information:
http://www.wiley.com
http://www.interscience.wiley.com/journal/arthritis

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>